With box warnings

Without box warnings

Branded

Generic

2 results

gavreto
(Pralsetinib)
Genentech, Inc.
Usage: GAVRETO is approved for treating adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients (12 years and older) with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy, specifically those who are radioactive iodine-refractory.
gavreto
(Pralsetinib)
Rigel Pharmaceuticals, Inc.
Usage: GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients aged 12 and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory.

Medications for Ret Gene Fusion Cancer

gavreto